Evidence map›Paper›PMID 42570199›Full record

ReviewInternational urology and nephrology2026

Efficacy, safety, and quality of life outcomes of [

Moosa Mubarika, Muhammad Maaz, Awon Muhammad, Syeda Emmama, Zaroon Mazhar, Muddassir Khalid, Jiya Kumari, Mohamed Hisham Alamin, Biruk Demisse Ayalew, Huzaifa Noor and 6 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Moosa MubarikaNishtar Medical University, Multan, Pakistan.
Muhammad MaazBacha Khan Medical College, Mardan, Pakistan.
Awon MuhammadKing Edward Medical University, Lahore, Pakistan.
Syeda EmmamaDow University of Health Sciences, Karachi, Pakistan.
Zaroon MazharNishtar Medical University, Multan, Pakistan.
Muddassir KhalidNishtar Medical University, Multan, Pakistan. dr.muddassirkhalid@gmail.com.ORCID http://orcid.org/0009-0004-0717-2777
Jiya KumariLiaquat University of Medical and Health Sciences, Jamshoro, Pakistan.
Mohamed Hisham AlaminFaculty of Medicine, International University of Africa, Khartoum, Sudan.
Biruk Demisse AyalewDepartment of Internal Medicine, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Huzaifa NoorNishtar Medical University, Multan, Pakistan.
Muhammad HassanArmy Medical College, Rawalpindi, Pakistan.
Muneeb KhawarKing Edward Medical University, Lahore, Pakistan.
Muhammad Hussnain SadiqNishtar Medical University, Multan, Pakistan.
Ghulam M S SyedDepartment of Clinical Imaging, PET/CT Centre, Hamad Medical Corporation, Doha, Qatar.
Laura EvangelistaHumanitas University, Milan, Italy.
Jamshed BomanjiInstitute of Nuclear Medicine, University College London Hospitals (UCLH) NHS Foundation Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveLutetium-177-PSMA radioligand therapy ([

methodsWe conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). Adult participants with PSMA-positive mCRPC (n = 2113) randomized to [ KEY FINDINGS AND LIMITATIONS: Six RCTs were analyzed. Primary intention-to-treat analysis did not demonstrate a statistically significant overall survival improvement (HR 0.81; 95% CI 0.62-1.06); however, sensitivity analysis adjusting for control-arm crossover suggested a survival benefit (HR 0.76; 95% CI 0.59-0.96). [ CONCLUSIONS AND CLINICAL IMPLICATIONS: [ PROSPERO REGISTRATION: The protocol of this systematic review and meta-analysis is registered under PROSPERO, having ID CRD420251151366.

Indexed as

[177Lu]Lu-PSMAMeta-analysisMetastatic castration-resistant prostate cancerRadioligand therapyTrial sequential analysis

Identifiers

PMID42570199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.